OpenURL Connection Search

Select item for more details and to access through your institution.

Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology.
Published in:
Proteomics, 2001, v. 1, n. 3, p. 377, doi. 10.1002/1615-9861(200103)1:3<377::AID-PROT377>3.0.CO;2-6
By:
- Tonge, Robert;
- Shaw, Joanne;
- Middleton, Brian;
- Rowlinson, Rachel;
- Rayner, Steve;
- Young, Janice;
- Pognan, Francois;
- Hawkins, Edward;
- Currie, Ian;
- Davison, Matthew
Publication type:
Article
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non- Hodgkin lymphoma pre-clinical models.
Published in:
British Journal of Haematology, 2013, v. 163, n. 1, p. 135, doi. 10.1111/bjh.12456
By:
- Maharaj, Lenushka;
- Marson, Charles M.;
- Middleton, Brian J.;
- Rioja, Alf S.;
- Perry, Jackie;
- Oakervee, Heather;
- Cavenagh, Jamie;
- Joel, Simon P.;
- Popat, Rakesh
Publication type:
Article
Improved measurement of drug exposure in the brain using drug-specific correction for residual blood.
Published in:
Journal of Cerebral Blood Flow & Metabolism, 2010, v. 30, n. 1, p. 150, doi. 10.1038/jcbfm.2009.200
By:
- Fridén, Markus;
- Ljungqvist, Helena;
- Middleton, Brian;
- Bredberg, Ulf;
- Hammarlund-Udenaes, Margareta
Publication type:
Article
High-throughput metabolic stability studies in drug discovery by orthogonal acceleration time-of-flight (OATOF) with analogue-to-digital signal capture (ADC).
Published in:
Rapid Communications in Mass Spectrometry: RCM, 2010, v. 24, n. 12, p. 1730, doi. 10.1002/rcm.4546
By:
- Temesi, David G.;
- Martin, Scott;
- Smith, Robin;
- Jones, Christopher;
- Middleton, Brian
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin’s lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- V. Repetto-Llamazares1., Ada H.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.237230
By:
- Malenge, Marion M.;
- Patzke, Sebastian;
- Ree, Anne H.;
- Stokke, Trond;
- Ceuppens, Peter;
- Middleton, Brian;
- Dahle, Jostein;
- Repetto-Llamazares, Ada H. V.
Publication type:
Article
An Optimized Automated Assay for Determination of Metabolic Stability Using Hepatocytes Assay Validation, Variance Component Analysis, and In VivoRelevance.
Published in:
Assay & Drug Development Technologies, 2007, v. 5, n. 3, p. 403, doi. 10.1089/adt.2007.059
By:
- Lykke Jacobson;
- Brian Middleton;
- Jan Holmgren;
- Stefan Eirefelt;
- Maria Fröjd;
- Anders Blomgren;
- Lena Gustavsson
Publication type:
Article
Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time.
Published in:
Journal of Computer-Aided Molecular Design, 2015, v. 29, n. 9, p. 795, doi. 10.1007/s10822-015-9836-5
By:
- Winiwarter, Susanne;
- Middleton, Brian;
- Jones, Barry;
- Courtney, Paul;
- Lindmark, Bo;
- Page, Ken;
- Clark, Alan;
- Landqvist, Claire
Publication type:
Article
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.
Published in:
Archives of Toxicology, 2017, v. 91, n. 8, p. 2849, doi. 10.1007/s00204-017-2002-1
By:
- Proctor, William;
- Foster, Alison;
- Vogt, Jennifer;
- Summers, Claire;
- Middleton, Brian;
- Pilling, Mark;
- Shienson, Daniel;
- Kijanska, Monika;
- Ströbel, Simon;
- Kelm, Jens;
- Morgan, Paul;
- Messner, Simon;
- Williams, Dominic
Publication type:
Article
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
Published in:
PLoS ONE, 2022, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0267543
By:
- Malenge, Marion M.;
- Maaland, Astri Fjelde;
- Repetto-Llamazares, Ada;
- Middleton, Brian;
- Nijland, Marcel;
- Visser, Lydia;
- Patzke, Sebastian;
- Heyerdahl, Helen;
- Kolstad, Arne;
- Stokke, Trond;
- Ree, Anne Hansen;
- Dahle, Jostein
Publication type:
Article
Diurnal variation in the femoral articular cartilage of the knee in young adult humans.
Published in:
Magnetic Resonance in Medicine, 2000, v. 43, n. 1, p. 126, doi. 10.1002/(SICI)1522-2594(200001)43:1<126::AID-MRM15>3.0.CO;2-#
By:
- Waterton, John C.;
- Solloway, Stuart;
- Foster, John E.;
- Keen, Michael C.;
- Gandy, Stephen;
- Middleton, Brian J.;
- Maciewicz, Rose A.;
- Watt, Iain;
- Dieppe, Paul A.;
- Taylor, Christopher J.
Publication type:
Article

Found: 18

Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology.

The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non- Hodgkin lymphoma pre-clinical models.

Improved measurement of drug exposure in the brain using drug-specific correction for residual blood.

High-throughput metabolic stability studies in drug discovery by orthogonal acceleration time-of-flight (OATOF) with analogue-to-digital signal capture (ADC).

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin’s lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.

<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.

An Optimized Automated Assay for Determination of Metabolic Stability Using Hepatocytes Assay Validation, Variance Component Analysis, and In VivoRelevance.

Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time.

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.

Anti-CD37 radioimmunotherapy with <sup>177</sup>Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.

Diurnal variation in the femoral articular cartilage of the knee in young adult humans.